Patents by Inventor Wais Kaihani

Wais Kaihani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11951146
    Abstract: Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of pterostilbene, Nigella sativa extract, green tea extract, and broccoli. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: April 9, 2024
    Assignee: Therapeutic Solutions International, Inc.
    Inventors: Thomas Ichim, Timothy G. Dixon, Famela Ramos, Wais Kaihani
  • Publication number: 20230333117
    Abstract: Disclosed are means and methods of identifying risk of suicide and/or suicidal ideation by assessment of immunologically related cytokines and cells. In one embodiment, a score, termed the “Campbell Score” is devised based on assessment of serum cytokines, ability of immune cells to make cytokines when stimulated ex vivo, and ability of immune cells to produce neurotransmitters when stimulated ex-vivo. In on embodiment the concentration of interleukin-6 is utilized as a means of assessing suicidal propensity along, and/or in combination with metabolites of the enzyme indolamine 2,3 deoxygenase.
    Type: Application
    Filed: August 23, 2021
    Publication date: October 19, 2023
    Applicant: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, Kalina O'CONNOR, Famela RAMOS, James VELTMEYER, Wais KAIHANI
  • Publication number: 20230277598
    Abstract: Disclosed are means, treatments and compositions of matter useful for treatment of chemotherapy/radiotherapy associated cognitive dysfunction. In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse cognitive dysfunction associated with chemotherapy and/or radiation therapy. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of neuroregeneration directly or indirectly.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 7, 2023
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Santosh KESARI, Thomas ICHIM, Timothy Dixon, Kalina O'CONNOR, Wais KAIHANI, Duncan HUNTER
  • Publication number: 20230107484
    Abstract: Disclosed are methods of reducing lung inflammation in acute respiratory distress syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.
    Type: Application
    Filed: October 4, 2022
    Publication date: April 6, 2023
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
  • Publication number: 20230085607
    Abstract: Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.
    Type: Application
    Filed: September 13, 2022
    Publication date: March 16, 2023
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
  • Publication number: 20230057356
    Abstract: Disclosed are means, compositions of matter and protocols useful for treatment of COVID-19 and/or other inflammatory pathologies through stimulation of T regulatory cells and/or T cells expressing CD73 using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment dosage of JadiCells needed to treat a patient is determined by the increase of T regulatory cells and/or CD73 expressing cells that are increased in number and/or activity subsequent to a test dose of JadiCells. In another embodiment stimulators of T regulatory cells and/or CD73 expressing T cells are utilized together with JadiCells in order to augment therapeutic activity. In some embodiments administration of JadiCell is performed with low dose interleukin-2 as a treatment for COVID-19 or other inflammatory related pathologies.
    Type: Application
    Filed: August 18, 2022
    Publication date: February 23, 2023
    Applicant: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
    Inventors: Thomas C. ICHIM, Famela RAMOS, James VELTMEYER, Timothy G. DIXON, Wais KAIHANI
  • Publication number: 20220370499
    Abstract: Disclosed are novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine. In some embodiment's genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the ?-Gal epitope (Gal?1,3Gal?1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.
    Type: Application
    Filed: May 19, 2022
    Publication date: November 24, 2022
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
  • Publication number: 20220362341
    Abstract: Disclosed are methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin-2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 17, 2022
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, Kalina O'CONNOR, Wais KAIHANI
  • Publication number: 20220193127
    Abstract: Disclosed are means, methods and compositions of matter useful for reduction of brain inflammation and prevention of opioid addiction and/or tolerance. In one embodiment the invention provides utilization of platelet rich plasma (PRP), alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiments PRP is admixed with oxytocin and administered intranasally in a patient at risk of opioid addiction. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil, and/or pterostilbene and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 23, 2022
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas Ichim, Timothy G. Dixon, Famela Ramos, Wais Kaihani, James Veltmeyer, Kalina O'Connor
  • Publication number: 20220160809
    Abstract: Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 26, 2022
    Inventors: Thomas Ichim, Timothy G. Dixon, Famela Ramos, Wais Kaihani